Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine

Kayser, Matthew S.; Klein, Hans; Paasch, I.; Pilaski, J.; Blenk, H.; Heeg, Klaus

doi:10.1002/jmv.1890170106

Cited by 37 publications

(19 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The diversity of natural JE strains was reflected in the neutralizing antibody responses of monkeys immunized with ChimeriVax-JE expressing the E protein of a Chinese (genotype 1) virus; prechallenge neutralizing antibodies to heterologous strains were significantly lower than to the homologous vaccine and were undetectable (titer of Ͻ20) in some cases (Table 4). Postchallenge anamnestic responses to heterologous strains were not measured in this study and will be reported elsewhere; however, it is likely that these responses would be characterized by a marked broadening of the antibody response across all JE strains (7,12,26). Cross-protection between heterologous members of the JE antigenic complex has been repeatedly demonstrated (8).…”

Section: Discussionmentioning

confidence: 97%

Chimeric Yellow Fever Virus 17D-Japanese Encephalitis Virus Vaccine: Dose-Response Effectiveness and Extended Safety Testing in Rhesus Monkeys

Monath¹,

Levenbook²,

Soike

et al. 2000

J Virol

128

View full text Add to dashboard Cite

ChimeriVax-JE is a live, attenuated recombinant virus prepared by replacing the genes encoding two structural proteins (prM and E) of yellow fever 17D virus with the corresponding genes of an attenuated strain of Japanese encephalitis virus (JE), SA14-14-2 (T. J. Chambers et al., J. Virol. 73:3095-3101, 1999). Since the prM and E proteins contain antigens conferring protective humoral and cellular immunity, the immune response to vaccination is directed principally at JE. The prM-E genome sequence of the ChimeriVax-JE in diploid fetal rhesus lung cells (FRhL, a substrate acceptable for human vaccines) was identical to that of JE SA14-14-2 vaccine and differed from sequences of virulent wild-type strains (SA14 and Nakayama) at six amino acid residues in the envelope gene (E107, E138, E176, E279, E315, and E439). ChimeriVax-JE was fully attenuated for weaned mice inoculated by the intracerebral (i.c.) route, whereas commercial yellow fever 17D vaccine (YF-Vax) caused lethal encephalitis with a 50% lethal dose of 1.67 log 10 PFU. Groups of four rhesus monkeys were inoculated by the subcutaneous route with 2.0, 3.0, 4.0, and 5.0 log 10 PFU of ChimeriVax-JE. All 16 monkeys developed low viremias (mean peak viremia, 1.7 to 2.1 log 10 PFU/ml; mean duration, 1.8 to 2.3 days). Neutralizing antibodies appeared between days 6 and 10; by day 30, neutralizing antibody responses were similar across dose groups. Neutralizing antibody titers to the homologous (vaccine) strain were higher than to the heterologous wild-type JE strains. All immunized monkeys and sham-immunized controls were challenged i.c. on day 54 with 5.2 log 10 PFU of wild-type JE. None of the immunized monkeys developed viremia or illness and had mild residual brain lesions, whereas controls developed viremia, clinical encephalitis, and severe histopathologic lesions. Immunized monkeys developed significant (>4-fold) increases in serum and cerebrospinal fluid neutralizing antibodies after i.c. challenge. In a standardized test for neurovirulence, ChimeriVax-JE and YF-Vax were compared in groups of 10 monkeys inoculated i.c. and analyzed histopathologically on day 30. Lesion scores in brains and spinal cord were significantly higher for monkeys inoculated with YF-Vax. ChimeriVax-JE meets preclinical safety and efficacy requirements for a human vaccine; it appears safer than yellow fever 17D vaccine but has a similar profile of immunogenicity and protective efficacy.Japanese encephalitis virus (JE), a mosquito-borne flavivirus, is endemic-epidemic throughout Asia. JE causes a devastating acute neurological illness with a case-fatality rate of approximately 35%. In developed countries such as Japan, Korea, and Taiwan, the disease incidence has been reduced to a low level over the past 30 years due principally to routine childhood immunization; however, virus transmission continues in the enzootic cycle (involving mosquitoes, birds, and pigs), mandating continuing human immunization. Unimmunized expatriates living in Asia, tourists, and military personnel are als...

show abstract

Section: Discussionmentioning

confidence: 97%

Chimeric Yellow Fever Virus 17D-Japanese Encephalitis Virus Vaccine: Dose-Response Effectiveness and Extended Safety Testing in Rhesus Monkeys

Monath¹,

Levenbook²,

Soike

et al. 2000

J Virol

128

View full text Add to dashboard Cite

show abstract

“…In addition, a broad spectrum flavivirus hemagglutination inhibition (HI) response in all subjects and low titer of neutralizing response against DEN2 in some subjects were developed. 20 Price et al 21 previously described a method for sequential flavivirus immunization, comprising a series of three immunizations with DEN2 and two heterologous viruses (YF and JE). However, unlike the present study, the sequence of YF followed by DEN2, without the addition of JE immunization, failed to confer cross-protective immunity.…”

Section: Discussionmentioning

confidence: 99%

Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All

Guirakhoo

Kitchener²,

Morrison³

et al. 2006

Human Vaccines

188

136

View full text Add to dashboard Cite

A randomized double-blind Phase I Trial was conducted to evaluate safety, tolerability, and immunogenicity of a yellow fever (YF)-dengue 2 (DEN2) chimera (ChimeriVax™-DEN2) in comparison to that of YF vaccine (YF-VAX ® ). Forty-two healthy YF naïve adults randomly received a single dose of either ChimeriVax™-DEN2 (high dose, 5 log plaque forming units [PFU] or low dose, 3 log PFU) or YF-VAX ® by the subcutaneous route (SC). To determine the effect of YF preimmunity on the ChimeriVax TM -DEN2 vaccine, 14 subjects previously vaccinated against YF received a high dose of ChimeriVax™-DEN2 as an open-label vaccine. Most adverse events were similar to YF-VAX ® and of mild to moderate intensity, with no serious side-effects. One hundred percent and 92.3% of YF naïve subjects inoculated with 5.0 and 3.0 log 10 PFU of ChimeriVax TM -DEN2, respectively, seroconverted to wt DEN2 (strain 16681); 92% of subjects inoculated with YF-VAX ® seroconverted to YF 17D virus but none of YF naïve subjects inoculated with ChimeriVax-DEN2 seroconverted to YF 17D virus. Low seroconversion rates to heterologous DEN serotypes 1, 3 and 4 were observed in YF naïve subjects inoculated with either ChimeriVax™-DEN2 or YF-VAX ® . In contrast, 100% of YF immune subjects inoculated with ChimeriVax™-DEN2 seroconverted to all 4 DEN serotypes. Surprisingly, levels of neutralizing antibodies to DEN 1, 2 and 3 viruses in YF immune subjects persisted after 1 year. These data demonstrated that (1) the safety and immunogenicity profile of the ChimeriVax™-DEN2 vaccine is consistent with that of YF-VAX ® , and (2) preimmunity to YF virus does not interfere with ChimeriVax TM -DEN2 immunization, but induces a long lasting and cross neutralizing antibody response to all 4 DEN serotypes. The latter observation can have practical implications toward development of a dengue vaccine.

show abstract

“…Previous studies of individuals who had received YF vaccine and were subsequently immunized with a heterologous flavivirus, such as tick-borne encephalitis (TBE), Japanese encephalitis (JE), or dengue, have shown broadening of the antibody response because of anamnestic responses against cross-reactive epitopes, and a boost in YF antibodies in such cases may occur. 11,12 However, these studies have not shown high levels of YF antibodies resulting from heterologous flavivirus infection, and moreover, neutralizing antibodies for YF are considered to be distinct from other flaviviruses. Abstract.…”

mentioning

confidence: 99%

Yellow Fever Vaccine Seroconversion in Travelers

Kay¹,

Chen²,

Sisti³

et al. 2011

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

To assess immunity after yellow fever (YF) 17D live-attenuated vaccination, we measured the antibody levels before vaccination and at 21 days and 8 months after vaccination in YF-naïve travelers. Thirty subjects were enrolled in the study, with 100% providing sera at 21 days and 86.6% providing sera at 8 months. All subjects seroconverted by day 21, and the geometric mean titers of the anti-YF antibodies decreased between day 21 and month 8 from 6,451 to 1,246. This study corroborates the high rates of seroconversion achieved by the live-attenuated YF vaccine.

show abstract

Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine

Cited by 37 publications

References 35 publications

Chimeric Yellow Fever Virus 17D-Japanese Encephalitis Virus Vaccine: Dose-Response Effectiveness and Extended Safety Testing in Rhesus Monkeys

Chimeric Yellow Fever Virus 17D-Japanese Encephalitis Virus Vaccine: Dose-Response Effectiveness and Extended Safety Testing in Rhesus Monkeys

Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All

Yellow Fever Vaccine Seroconversion in Travelers

Contact Info

Product

Resources

About